Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Neto, José Abraão Carneiro; Santos, Sara; Orge, Glória; Tanajura, Davi; Passos, Lúcia; Oliveira, Cassius José Vitor de; Andrade, Rosana; Melo, Cláudio Galeno de; Barroso, Ubirajara; Carvalho, Edgar M.

doi:10.1016/j.bjid.2017.10.009

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed an improvement in subjective symptoms using OABSS, an increase in cystometric capacity. The results of these changes in subjective and objective findings are consistent with other reports by Carneiro et al 17,18 Furthermore, we also examined each item of the OABSS and found that the most important symptom of OAB, urinary urgency, improved after BoNTA therapy in all patients. In addition, we found an elimination of detrusor overactivity through urodynamic studies.…”

Section: Discussionsupporting

confidence: 91%

“…Previous reports have indicated that BoNTA intravesical instillation therapy was effective in patients with neurogenic OAB caused by multiple sclerosis or spinal cord injury 15,16 . However, there have been only two reports of the same group on the efficacy of BoNTA in patients with neurogenic OAB due to HAM/TSP refractory to conventional treatment 17,18 . Carneiro et al reported that total OABSS improved from 13.0 to 1.0 in 10 patients (3 probable HAM/TSP and 7 HAM/TSP) 30 days after BoNTA treatment 13 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

et al. 2021

View full text Add to dashboard Cite

Introduction Neurogenic overactive bladder is a main feature of human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. We successfully performed intravesical onabotulinumtoxinA therapy for refractory neurogenic overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis. Case presentation We retrospectively reviewed four neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis who underwent bladder wall injections of onabotulinumtoxinA from April to October 2020. All patients were female. Their median age was 66 (range, 63–71) years. They were previously treated with β3‐adrenergic receptor agonists or anticholinergic drugs alone or in combination for ≥12 weeks. However, insufficient results were obtained. After 4 weeks of intravesical onabotulinumtoxinA therapy, overactive bladder symptoms improved and maximum cystometric capacity increased in all cases. Conclusion Intravesical onabotulinumtoxinA therapy may be useful for treating refractory overactive bladder due to human T‐cell leukemia virus type 1‐associated myelopathy/tropical spastic paraparesis.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

et al. 2021

View full text Add to dashboard Cite

show abstract

Lower urinary tract dysfunction in uncommon neurological diseases, Part III: A report of the Neuro-urology Promotion Committee of the International Continence Society

Sakakibara,

Sinha,

De Wachter

et al. 2024

Continence

View full text Add to dashboard Cite

Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background While bladder dysfunction is observed in the majority of patients with human T cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM), it is also observed in patients who do not fulfill all diagnostic criteria for HAM. These patients are classified as having possible or probable HAM/TSP. However, it remains unclear whether the severity and progression of bladder dysfunction occurs similarly between these two groups. Objective Compare the severity and evolution of bladder dysfunction in HTLV-1-infected patients with possible and definite HAM/TSP. Methods The present prospective cohort study followed 90 HTLV-1 patients with possible HAM/TSP and 84 with definite HAM/TSP between April 2011 and February 2019. Bladder dysfunction was evaluated by bladder diary, overactive bladder symptoms scores (OABSS) and urodynamic studies. Bladder dysfunction progression was defined as the need for clean self-intermittent catheterization (CIC). Results At baseline, nocturia, urgency and OABSS scores were worse in definite compared to possible HAM/TSP patients. The main urodynamic finding was detrusor overactivity, present in 77.8% of the patients with definite HAM/TSP versus 58.7% of those with possible HAM/TSP (P = 0.05). Upon study conclusion, the cumulative frequency of patients requiring CIC increased in both groups, from 2 to 6 in possible HAM/TSP and from 28 to 44 in definite HAM/TSP patients. The estimated time to need for CIC was 6.7 years (95%CI 6.5–7.0) in the possible HAM/TSP group compared to 5.5 years (95%CI 4.8–6.1) in the definite HAM/TSP group. Conclusions Although both groups showed similarities in bladder dysfunction and tended to progress to requiring CIC over time, patients with possible HAM/TSP presented less severe manifestations at baseline and progressed more slowly than those with definite HAM/TSP.

show abstract

Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Abstract: Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder.

Cited by 4 publications

References 29 publications

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series

Lower urinary tract dysfunction in uncommon neurological diseases, Part III: A report of the Neuro-urology Promotion Committee of the International Continence Society

Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study

Contact Info

Product

Resources

About